mRNA transcriptome profiling of human hepatocellular carcinoma cells HepG2 treated with Catharanthus roseus-silver nanoparticles

Table 1 Summary of genome mapping

Sample	Total clean reads	Total mapping ratio	Uniquely mapping ratio
Untreated HepG2	70025052	95.94%	76.60%
C. roseus-AgNPs treated HepG2	72598578	95.82%	75.94%

C. roseus-AgNPs: Catharanthus roseus-silver nanoparticles.

Table 2 Summary of gene mapping ratio

Sample	Total clean reads	Total mapping ratio	Uniquely mapping ratio
Untreated HepG2	70025052	66.79%	63.92%
C. roseus-AgNPs treated HepG2	72598578	62.94%	60.15%

C. roseus-AgNPs: Catharanthus roseus-silver nanoparticles.

Table 3 Pathway functional enrichment results

Pathway ID	Pathway	Genes	Hits	Adj P value
K05200	Pathway in cancer	FAS, GADD45A, BAX, PMAIP, BID, JUN, CXCL8, HMOX1, STAT1, FOS, CEBPA, VEGFA, FGF5, EGF, RHOA, FADD, FH, SMAD, MTOR, NFκBIA, CDKN1A, WNT4a, WNT7Aa, FGFR3a, BMP4a, CDK4a, CDK2a, MDMa	29/530	3.28E-12
K04115	p53 signaling pathway	FAS, GADD45A, SERPINE, THBS1, CDK4, BAX, CDK2, PERP, SESN1, SESN2, PMAIP1, BID, IGFBP3a, MDM2a	14/72	1.28E-13
K04210	Apoptosis	FAS, GADD45A, BAX, PMAIP1, BID, JUN, FOS, FADD, NFKBIA, BCL2A1, ATF4, MCL1, TNFSF10a, RIPK1a	14/136	9.61E-10
K04144	Endocytosis	ARF6, RHOA, EHD2, FGFR3, HSPA6, HSPA1L, VPS28, EEA1, VPS25, TSG101, STAM, SMAD, EHD4, LDLR, TFRCa, MDM2a	16/244	4.08E-08
K04010	MAPK signaling pathway	FAS, GADD45A, JUN, FOS, VEGFA, FGF5, CDKN1A, EGF, ATF4, HSPA6, HSPA1L, CDKN1A, HSPB1, DUSP1, NR4A1, EFNA4a, FGFR3a, ERBB3a, SKP2a	16/295	5.58E-07
K04668	TNF signalling pathway	FAS, JUN, FOS, FADD, NFKBIA, ATF4, RIPK1a, CCL2, NOD2, CCL20a	10/110	9.07E-07
K04350	TGF beta signaling pathway	THBS1, RHOA, SMAD2, SMAD4, BMP4, SMAD7, BAMBI, BMP6	8/90	1.66E-05
K02010	Cell cycle	GADD45A, SOX15, CDK4a, CDK2a, MDM2, SMAD2, SMAD4, CDKN1A, PCNAa, MCM3a, SKP2a	9/124	2.09E-05
K04978	Mineral absorption	HMOX1, MT1F, MT1X, MT1H, MT1B, FTH1	6/51	3.58E-05

^aDownregulated genes.